Tag: anthrax

April 12, 2018

Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries

Emergent BioSolutions (NYSE:EBS) announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorization of BioThrax® (Anthrax Vaccine Adsorbed)...
January 23, 2018

Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.

Altimmune (Nasdaq:ALT) a clinical-stage immunotherapeutics company, today announced that it has received a Notice of Allowance from the United States...
April 12, 2017

5 Top Pharma Stocks of Q1 2017 on the TSX

The Investing News Network takes a look at some of the best-performing pharmaceutical stocks on the TSX during the first...
March 27, 2017

Allergan and Paratek Show Positive Results For Acne Treatment

Allergan (NYSE:AGN) and Paratek Pharmaceuticals (NASDAQ:PRTK) announced successful initial results for the two and Phase 3 trials of their acne...
January 27, 2017

Emergent BioSolutions Receives Approval for Large-Scale Manufacturing of BioThrax

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health,...
January 3, 2017

GeoVax Announces Formation of Scientific Advisory Board

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today the formation of its inaugural...
December 13, 2016

Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017

Paratek Pharmaceuticals announced today that it projects its ongoing pivotal Phase 3 clinical study evaluating omadacycline for the treatment of...